2024
Real‐world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer
Sukumar J, Sardesai S, Ni A, Williams N, Johnson K, Quiroga D, Ramaswamy B, Wesolowski R, Cherian M, Stover D, Gatti‐Mays M, Pariser A, Sudheendra P, George M, Lustberg M. Real‐world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer. Cancer Medicine 2024, 13: e7317. PMID: 38895891, PMCID: PMC11185945, DOI: 10.1002/cam4.7317.Peer-Reviewed Original ResearchConceptsOvarian suppressionEndocrine therapyAdjuvant endocrine therapyBreast cancerClinicopathological featuresAromatase inhibitorsOS useHR+/HER2+ breast cancerOptimal adjuvant endocrine therapyHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Real-world treatment patternsCohort of premenopausal womenAnti-HER2 therapyPremenopausal breast cancerClinicopathological risk factorsMultivariable logistic regression assessed associationsLogistic regression assessed associationsPremenopausal BCPrescribed tamoxifenPremenopausal patientsPremenopausal womenBC subtypesContemporary cohortAnti-HER2
2022
Aromatase-Inhibitor-Induced Musculoskeletal Inflammation Is Observed Independent of Oophorectomy in a Novel Mouse Model
Young N, Hampton J, Sharma J, Jablonski K, DeVries C, Bratasz A, Wu L, Lustberg M, Reinbolt R, Jarjour W. Aromatase-Inhibitor-Induced Musculoskeletal Inflammation Is Observed Independent of Oophorectomy in a Novel Mouse Model. Pharmaceuticals 2022, 15: 1578. PMID: 36559029, PMCID: PMC9785754, DOI: 10.3390/ph15121578.Peer-Reviewed Original ResearchAI treatmentFemale BALB/cHalf of patientsPositive breast cancerPro-inflammatory cytokines analysisFuture interventional strategiesNovel mouse modelBALB/cPhysiological estrogen levelsNovel animal modelMusculoskeletal inflammationSerum cytokinesEstrogen deficiencyCytokine analysisEstrogen combinationEstrogen levelsEstrogen productionAromatase inhibitorsBreast cancerHuman PBMCsInterventional strategiesMouse modelAnimal modelsNFκB activationBioluminescent imaging
2017
Genomic risk prediction of aromatase inhibitor‐related arthralgia in patients with breast cancer using a novel machine‐learning algorithm
Reinbolt R, Sonis S, Timmers C, Fernández‐Martínez J, Cernea A, de Andrés‐Galiana E, Hashemi S, Miller K, Pilarski R, Lustberg M. Genomic risk prediction of aromatase inhibitor‐related arthralgia in patients with breast cancer using a novel machine‐learning algorithm. Cancer Medicine 2017, 7: 240-253. PMID: 29168353, PMCID: PMC5773952, DOI: 10.1002/cam4.1256.Peer-Reviewed Original ResearchConceptsAromatase inhibitor-related arthralgiaAromatase inhibitorsBreast cancerSystematic chart reviewBreast cancer patientsTHU0062 Novel animal model of aromatase inhibitor-induced arthralgia suggests an estrogen-independent inflammatory mechanism
Young N, Thomas E, Snoad B, Sharma J, Mobeen M, DeVries A, Bratasz A, Lustberg M, Jarjour W, Reinbolt R. THU0062 Novel animal model of aromatase inhibitor-induced arthralgia suggests an estrogen-independent inflammatory mechanism. Annals Of The Rheumatic Diseases 2017, 76: 222. DOI: 10.1136/annrheumdis-2017-eular.5424.Peer-Reviewed Original ResearchBreast cancer patientsEarly-stage breast cancer patientsAromatase inhibitor-related arthralgiaStage breast cancer patientsBreast cancer researchSerum cytokine levelsBreast cancer survivorsAromatase inhibitorsNovel animal modelInflammatory mechanismsCancer patientsCytokine levelsCancer survivorsMusculoskeletal symptomsRisk factorsHistopathological analysisProspective characterizationAI treatmentHormone receptor-positive breast cancer patientsAnimal modelsReceptor-positive breast cancer patientsNFκB activationAromatase inhibitor-induced arthralgiaBioluminescent imagingKnee jointGenomic risk prediction of aromatase inhibitor-related arthralgias (AIA) in breast cancer (BC) patients using a novel analytical algorithm (NAA).
Reinbolt R, Sonis S, Timmers C, Fernández-Martínez J, deAndrés-Galiana E, Hashemi S, Miller K, Ramaswamy B, Wesolowski R, Noonan A, Dewani S, Williams N, Sardesai S, Pilarski R, Lustberg M. Genomic risk prediction of aromatase inhibitor-related arthralgias (AIA) in breast cancer (BC) patients using a novel analytical algorithm (NAA). Journal Of Clinical Oncology 2017, 35: 10102-10102. DOI: 10.1200/jco.2017.35.15_suppl.10102.Peer-Reviewed Original ResearchAromatase inhibitor-related arthralgiaAromatase inhibitorsSystematic chart reviewBreast cancer patientsCase-control studyPeripheral blood cellsAsymptomatic patientsChart reviewTherapy switchTreatment initiationTreatment complianceBC patientsGenomic risk predictionCancer patientsBreast cancerStage IPatientsClinical phenotypeBlood cellsSNP groupGermline DNACandidate gene studiesStrong association
2015
Impact of breast cancer treatment on body mass index (BMI) over time.
Reinbolt R, Pan X, Wandell K, Pilarski R, Layman R, Mrozek E, Ramaswamy B, Wesolowski R, Lustberg M. Impact of breast cancer treatment on body mass index (BMI) over time. Journal Of Clinical Oncology 2015, 33: 94-94. DOI: 10.1200/jco.2015.33.28_suppl.94.Peer-Reviewed Original ResearchBody mass indexBreast cancer patientsEndocrine therapyAromatase inhibitorsWeight gainBMI changeCancer patientsEarly placebo-controlled trialsInitial body mass indexEarly-stage breast cancerHigher body mass indexBody mass index (BMI) changeBreast cancer patient cohortsPlacebo-controlled trialRetrospective chart reviewStage breast cancerBreast cancer treatmentCancer patient cohortsBreast cancer therapyQuality of lifeDifferent treatment groupsAI therapyChart reviewTreatment initiationMass indexAtrophic Vaginitis in Breast Cancer Survivors: A Difficult Survivorship Issue
Lester J, Pahouja G, Andersen B, Lustberg M. Atrophic Vaginitis in Breast Cancer Survivors: A Difficult Survivorship Issue. Journal Of Personalized Medicine 2015, 5: 50-66. PMID: 25815692, PMCID: PMC4493485, DOI: 10.3390/jpm5020050.Peer-Reviewed Original ResearchBreast cancer survivorsAtrophic vaginitisCancer survivorsEndocrine therapySelective estrogen receptor modulatorsSystemic estrogen therapyPatient-reported symptomsEstrogen receptor modulatorsVariety of symptomsQuality of lifeVaginal moistureEstrogen therapyLifestyle modificationLocal estrogenTopical estrogenVaginal drynessGynecological examinationSurvivorship issuesGenital skinOvarian failureVaginal dischargeSystematic therapyAromatase inhibitorsReceptor modulatorsBreast cancer
2011
Phase II Trial of Neoadjuvant Exemestane in Combination With Celecoxib in Postmenopausal Women Who Have Breast Cancer
Lustberg M, Povoski S, Zhao W, Ziegler R, Sugimoto Y, Ruppert A, Lehman A, Shiels D, Mrozek E, Ramaswamy B, Layman R, Brueggemeier R, Shapiro C. Phase II Trial of Neoadjuvant Exemestane in Combination With Celecoxib in Postmenopausal Women Who Have Breast Cancer. Clinical Breast Cancer 2011, 11: 221-227. PMID: 21729671, PMCID: PMC3440773, DOI: 10.1016/j.clbc.2011.03.022.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAndrostadienesAntineoplastic AgentsBreast NeoplasmsCarcinoma, LobularCelecoxibCyclooxygenase 2Cyclooxygenase 2 InhibitorsDrug Therapy, CombinationFemaleFollow-Up StudiesHumansImmunoenzyme TechniquesLymphatic MetastasisMiddle AgedNeoadjuvant TherapyNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPostmenopausePyrazolesReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneSulfonamidesSurvival RateTreatment OutcomeConceptsPathological complete responsePhase II trialEstrogen receptorKi-67Neoadjuvant exemestaneII trialPostmenopausal womenCOX-2Breast cancerDefinitive breast cancer surgeryCOX-2 inhibitor celecoxibSerious cardiac eventsAnti-tumor responseBreast cancer surgeryAddition of celecoxibCOX-2 expressionMajority of womenStable diseaseCardiac eventsPartial responseComplete responseCancer surgeryCore biopsyAromatase inhibitorsHER-2